+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ERIS

Eris Lifesciences Share Price

₹1,358.50 -21.8 (-1.58%)
25.36% Fall from 52W High

14 Aug, 2026 3:50 PM (IST)

Eris Lifesciences live price: ₹1,358.50. It opened at ₹1,381 vs previous close ₹1,380; intraday high/low: ₹1,381/₹1,356. The 50 & 200 DMA stand at ₹1,402.50/₹1,430.60.

Eris Lifesciences Performance

  • Today's Low
  • ₹1,356
  • Today's High
  • ₹1,381
  • 52 Week Low
  • ₹1,200
  • 52 Week High
  • ₹1,820
  • Open Price₹1,381
  • Previous Close₹1,380
  • Volume40,519
  • 50 DMA₹1,402.50
  • 100 DMA₹1,407.20
  • 200 DMA₹1,430.60

Eris Lifesciences Chart

Investment Returns

  • Over 1 Month -6.3%
  • Over 3 Month + 2.1%
  • Over 6 Month -3.95%
  • Over 1 Year -18.89%

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.2
  • PEG Ratio
  • 0.4
  • Market Cap Cr
  • 18,827
  • P/B Ratio
  • 4.8
  • Average True Range
  • 38.3
  • EPS
  • 46.5
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -13.6
  • RSI
  • 46.01
  • MFI
  • 70.76

Latest Stock News Updates

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

as attached

Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

As Attached

Eris Lifesciences Ltd - 540596 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Working Capital Term Loan From Axis Bank

as attached

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,358.50
-21.8 (-1.58%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,394.20
  • 50 Day
  • ₹1,402.50
  • 100 Day
  • ₹1,407.20
  • 200 Day
  • ₹1,430.60

Resistance and Support

1365.23 Pivot Speed
  • R3 1,436.00
  • R2 1,410.80
  • R1 1,395.50
  • S1 1,355.00
  • S2 1,329.80
  • S3 1,314.50

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-29 Quarterly Results
2026-05-20 Audited Results & Interim Dividend
2026-02-13 Quarterly Results
2025-11-24 Preferential issue of shares Inter-alia, To consider the protposal of issuance ofequity shares of the Company by way of a preferential issue for consideration other than cash..
2025-11-12 Quarterly Results
Date Purpose Remarks
2026-05-29 INTERIM Rs.7.21 per share(721%)Interim Dividend
2025-02-13 INTERIM Rs.7.35 per share(735%)Interim Dividend
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend
View Eris Lifesciences Dividend History Arrow

Eris Lifesciences Shareholding Pattern

54.14%
19.39%
18.88%
5.76%
1.83%

About Eris Lifesciences

ERIS Lifesciences manufactures, markets, and sells generic drugs. The Company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets. Eris Lifesciences also focuses on hypertension, anti-diabetes, metabolic disorders, lipid lowering, and therapeutic areas. Eris Lifesciences serves the pharmaceutical markets in India. View More
  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,358 As on 14 August, 2026 | 17:28

The Market Cap of Eris Lifesciences is ₹18826.5 Cr As on 14 August, 2026 | 17:28

The P/E ratio of Eris Lifesciences is 29.2 As on 14 August, 2026 | 17:28

The PB ratio of Eris Lifesciences is 4.8 As on 14 August, 2026 | 17:28

The 52 week High & Low of Eris Lifesciences is ₹1820/₹1200 respectively As on 14 August, 2026 | 17:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23